Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who mostly recommend buying or holding the stock. Other firms like Truist, Argus, and UBS raised their targets, reflecting varied analyst sentiment. CEO J. Patrick Gallagher Jr. highlights that clients are using savings from lower property premiums to increase coverage, supporting a positive outlook despite mixed analyst views.
Arthur J. Gallagher's growth outlook is highlighted by an expected 6% organic growth in Q3. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 07, 2026 19:41 WIB: out of 85 priced US Financials stocks, 17 rose and 66 fell. Notable movers include HOOD at USD 108.61 with a 1-day change of -3.03% and a typical hold time on Pluang of 75 days, MARA at USD 10.65 down 2.92%, and RIOT at USD 18.40 down 2.80% with 92% sell order activity on Pluang.
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
Barclays has lowered its price target for Netflix shares from $80 to $70 due to concerns over slower revenue growth and rising content costs, especially for live programming. Despite Netflix's large subscriber base of 325 million, the company faces p...
Jefferies analyst Andrew Tsai lowered Rocket Pharmaceuticals' price target to $2.95, with shares trading at $2.48. The company is advancing its gene therapy for Danon disease, RP-A501, with an FDA-aligned pivotal study plan. Rocket secured $35 millio...
Eight Wall Street firms raised their price targets for Zscaler following the company's $10 billion Annual Recurring Revenue (ARR) goal announcement, with targets now implying a 29% upside from current prices. While most analysts maintain Buy or Overw...
Xencor, a biotech company specializing in antibody engineering, secured a $105 million settlement with Alexion, improving its financial runway. This funding is expected to support the company through the FDA's PDUFA decision on obexelimab, a partnere...
